Varoglutamstat第2阶段b 研究表明,有良好耐用药物的糖尿病患者的肾功能有了显著改善。 2024 Phase 2b Varoglutamstat study showed a significant kidney function improvement in diabetic patients with a well-tolerated drug.

Vivoryon治疗学N.V.报告说,它在2024年ASN肾病周对可能治疗肾病的Varoglutamstat(一种潜在的肾病治疗)进行的第二阶段b研究取得了有希望的成果。 Vivoryon Therapeutics N.V. reported promising results from its Phase 2b study of Varoglutamstat, a potential kidney disease treatment, at ASN Kidney Week 2024. 研究表明,肾功能有了显著改善,与安慰剂相比,eGFR增加了3.4毫升/分钟/年,糖尿病患者增加了8.2毫升/分钟/年。 The study showed a significant improvement in kidney function, with a 3.4mL/min/year increase in eGFR compared to placebo, and 8.2mL/min/year in diabetic patients. 药物耐受性良好,没有增加蛋白尿风险. The drug was well-tolerated with no increased proteinuria risk. 该公司计划为糖尿病肾病患者开展进一步研究。 The company plans further studies for patients with advanced diabetic kidney disease.